Posted inHematology-Oncology news
CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis
A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction in TP53-mutated or other molecular subgroups.